Another study involving 2660 stage 1 or 2 NB patients has shown that patients diagnosed with tumors with MYCN amplification have a significantly worse EFS and inferior overall survival (OS) compared with patients without MYCN amplification.146. Here, MYCN is linked to neuroblastoma.